Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic Imiquimod cream used for treating skin disorders.
Glenmark Generics Inc, the company's subsidiary has received final abbreviated new drug approval (ANDA) from the United States Food and Drug Administration (USFDA) for its Imiquimod cream 5% and has commenced shipping it, Glenmark Pharmaceuticals said in a statement.
The cream is a generic version of Medicis Pharmaceutical Corporation's Aldara, it added.
"According to IMS Health sales data for 12 month period ending December 2011, Imiquimod cream garnered annual sales of approximately $244 million," the company said.
The company has 77 products authorised for distribution in the US market and 40 ANDAs pending approval with USFDA, it added.
Scrips of Glenmark Pharmaceuticals were today trading at Rs 292 per share in the afternoon trade on BSE, down one% from its previous close.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app